Basic knowledge on BCR-ABL1-positive extracellular vesicles.

BCR-ABL cell communication chronic myeloid leukemia extracellular vesicles microenvironment microvesicles translational medicine

Journal

Biomarkers in medicine
ISSN: 1752-0371
Titre abrégé: Biomark Med
Pays: England
ID NLM: 101312535

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 10 4 2020
medline: 3 8 2021
entrez: 10 4 2020
Statut: ppublish

Résumé

Chronic myelogenous leukemia (CML) is a hematological malignancy characterized by the excessive proliferation of myeloid progenitors. In the case of CML, these extracellular vesicles (EVs) were shown to communicate with hematopoietic stem cells, mesenchymal stem cells, myeloid derived suppressor cells and endothelial cells determining a beneficial microenvironment for the CML clone. Moreover, as these EVs are marked through BCR-ABL1, they were shown to be useful in clinical research in determining the grade of molecular remission with further studies being needed to determine if they are better or worse at predicting CML relapse. More than this, we consider BCR-ABL1-positive EVs to represent only a stepping-stone for other malignancies that also present fusion genes that are loaded in EVs.

Identifiants

pubmed: 32270699
doi: 10.2217/bmm-2019-0510
doi:

Substances chimiques

BCR-ABL1 fusion protein, human 0
Fusion Proteins, bcr-abl EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

451-458

Auteurs

Ancuta Jurj (A)

Research Center for Functional Genomics, Biomedicine & Translational Medicine, Iuliu Hatieganu University of Medicine & Pharmacy, 23 Marinescu Street, 400337, Cluj-Napoca, Romania.

Sergiu Pasca (S)

Department of Hematology, Iuliu Hatieganu University of Medicine & Pharmacy, 21 December Boulevard, 400124, Cluj-Napoca, Romania.

Patric Teodorescu (P)

Department of Hematology, Iuliu Hatieganu University of Medicine & Pharmacy, 21 December Boulevard, 400124, Cluj-Napoca, Romania.
Department of Hematology, Ion Chiricuta Clinical Cancer Center, Republicii Street 34-36, 400015, Cluj-Napoca, Romania.

Ciprian Tomuleasa (C)

Research Center for Functional Genomics, Biomedicine & Translational Medicine, Iuliu Hatieganu University of Medicine & Pharmacy, 23 Marinescu Street, 400337, Cluj-Napoca, Romania.
Department of Hematology, Iuliu Hatieganu University of Medicine & Pharmacy, 21 December Boulevard, 400124, Cluj-Napoca, Romania.
Department of Hematology, Ion Chiricuta Clinical Cancer Center, Republicii Street 34-36, 400015, Cluj-Napoca, Romania.

Ioana Berindan-Neagoe (I)

Department of Hematology, Iuliu Hatieganu University of Medicine & Pharmacy, 21 December Boulevard, 400124, Cluj-Napoca, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH